OncoResponse, Inc, based in Houston, TX, is a biotechnology company focused on discovering novel cancer immunotherapies by interrogating the human immune system. Leveraging elite immune responses, OncoResponse aims to develop monoclonal antibodies that target immunosuppressive myeloid biology in the tumor microenvironment to enhance immune activity and transform cold tumors into hot ones.
With a mission to attack cancer based on clues from Elite Cancer Responders, OncoResponse utilizes a clinically validated Technology Platform to identify authentic human antibodies associated with immunosuppression. Through strategic partnerships and a promising preclinical pipeline, the company is dedicated to advancing immuno-oncology and improving outcomes for cancer patients.
Generated from the website
